Granted Patent B2

US 12,433,573 · App. 18/507,494 · Granted Oct 7, 2025

Inventors: Ridhi Tariyal (Oakland, CA); Stephen K. Gire (Oakland, CA)

Assignee: NEXTGEN JANE, INC.

A61B10/0045A61B10/0096B01L3/00B01L3/5029B01L3/523C12Q1/6806A01N1/122A61B2010/0006A61B2010/0074A61B2010/0216B01L2200/0621B01L2200/16B01L2300/069B01L2300/0832B01L2300/0851B01L2400/0683C12M33/02C12Q1/04C12Q1/6883C12Q2600/158G01N2001/028

Abstract

Claims (24)

1. A method for assaying for a presence or absence of a vaginal or menstrual microbiome, comprising:

obtaining a sample collector enclosed in an extractor, wherein the sample collector comprises an absorbent-diffuse material and is configured to collect a biological sample from a vaginal canal of a female subject wherein the biological sample comprises vaginal or menstrual fluid,

and wherein the vaginal or menstrual fluid is retained on the sample collector;

releasing or extracting nucleic acid from the sample collector with a solution comprised in the extractor, wherein a moveable compression element closes onto a breakable reagent compartment of the extractor to release the solution, wherein the solution contacts the sample collector when the sample collector is fully enclosed in the extractor, wherein the solution is free to flow between the sample collector and the extractor; and

subjecting the released or extracted nucleic acid to a sequencing analysis, whereby the sequencing analysis detects a presence or absence, or change of expression level of at least one biomarker indicative of a vaginal or menstrual microbiome.

2. The method of claim 1 , wherein the biological sample comprises cervicovaginal fluid.

3. The method of claim 1 , wherein the biological sample comprises menstrual fluid.

4. The method of claim 1 , wherein the solution preserves the released or extracted nucleic acid.

5. The method of claim 1 , wherein the sample collector is configured to be inserted into the vagina or vaginal canal of the female subject.

6. The method of claim 5 , wherein the sample collector is a tampon.

7. The method of claim 5 , wherein the sample collector is not a vaginal swab.

8. The method of claim 1 , wherein the sample collector is configured to collect the vaginal or menstrual fluid when placed outside of the body of the female subject.

9. The method of claim 1 , wherein the sequencing analysis is selected from the group consisting of 16S rRNA sequencing, methylation sequencing, long-noncoding RNA sequencing, microRNA sequencing, RNA deep sequencing, genomic DNA sequencing, and cDNA sequencing.

10. The method of claim 1 , wherein the solution is comprised within a breakable reagent compartment in the extractor.

11. The method of claim 10 , wherein the solution is released from the breakable reagent compartment when the extractor is closed.

12. The method of claim 1 , wherein the detection of the presence or absence of a vaginal microbiome comprises detection of a bacteria, a fungus, a yeast, a virus, a viroid, a protozoa or a parasite.

13. The method of claim 12 , wherein the method further detects the level of the bacteria, the fungus, the yeast, the virus, the viroid, the protozoa or the parasite.

14. The method of claim 13 , wherein the bacteria is a Lactobacillus species, an Atopobium vaginae , a Gardnerella vaginalis , a Chlamydia trachomatis , a Neisseria gonorrhoeae , a Treponema pallidum , a Clostridiales species, a Megasphaera species, or a Sneathia species.

15. The method of claim 1 , wherein the presence or absence of the vaginal microbiome indicates the female subject's vaginal health.

16. The method of claim 1 , wherein the presence or absence of the vaginal microbiome indicates a pregnancy complication or preterm labor.

17. The method of claim 1 , wherein the presence or absence of the vaginal microbiome indicates an infection of the female subject's genital or reproductive tract.

18. The method of claim 17 , wherein the infection is a yeast infection, a fungal infection, a bacterial infection, a viral infection, a viroid infection, a parasite infection, or a protozoa infection.

19. The method of claim 1 , further comprising assaying the vaginal or menstrual fluid for a biomarker for the presence or absence of a health condition of the female subject selected from the group consisting of cancer, pregnancy, fertility, semen, hormone levels, endometriosis, polycystic ovarian syndrome, reproductive disorders, immune disorders, and nutrient levels.

20. The method of claim 19 , further comprising assaying the vaginal or menstrual fluid for the expression level of the biomarker by sequencing analysis.

Assignments (1)

Continuity (6)

References Cited (335)